Michigan State University
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Michigan State University
Bausch seeks to add eyecare assets in Allegro deal. AstraZeneca hopes preclinical PCSK9 inhibitor from Dogma can compete with dyslipidemia leaders. Exelixis options ADC candidates from Catalent and NBE.
Advances in computational power and in the application of quantum mechanics to drug modeling are rekindling interest in in silico drug design. The prize is a steep reduction in the cost of discovery and an increase in the quality of lead candidates.
START-UP's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies in in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical equipment & supplies.
After years of working for a "cure" for breast cancer, researchers have come to realize the enormity of the task. Although therapeutic advances are making it possible for women with advanced breast cancer to live longer, more comfortable lives, scientists still have a long way to go before they fully understand this complex disease. At this year's Society of Surgical Oncology's annual Cancer Symposium, researchers zeroed in on several key areas that could eventually unlock new methods of controlling, and possibly eliminating, this all too pervasive threat.
- Academic and Research Institutions